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 Transforming growth factor -β (TGF-β) plays an important role in the progression 
of prostate cancer. It acts as a tumor suppressor in normal epithelial cells but as a tumor 
promoter in advanced prostate cancer cells. The PI3-kinase pathway has been shown to 
play integral roles in many cellular processes including cell proliferation, survival, and 
cell migration in many cell types. PI3-kinase pathway mediates TGF-β effects on prostate 
cancer cell migration and invasion. Phosphatase and tensin homolog (PTEN), a tumor 
suppressor gene, inhibits PI3-kinase pathway and is frequently mutated in prostate 
cancers. In this present study, we investigated possible roles of PTEN in TGF-β effects 
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on proliferation, migration, and the activation of PI3-kinase/AKT pathway in prostate 
cancer cells. PTEN was expressed in DU145 cells; however PC3 cells lack PTEN 
expression. TGF-β1 and TGF-β3 had no effect on PTEN mRNA levels but both isoforms 
increased PTEN protein levels in DU145 and RWPE1 cells, suggesting that TGF-β may 
mediate regulation of PTEN protein stability. TGF-β1 and TGF-β3 increased PTEN 
protein levels even in the presence of cycloheximide, a protein synthesis inhibitor, in 
DU145 cells. In addition, TGF-β upregulated phosphorylation of PTEN, stabilizing 
PTEN protein. Increase of PTEN protein levels in these cells may also indicate that 
PTEN may mediate TGF-β effects on cell proliferation. Knockdown of PTEN in DU145 
cells resulted in significant increase in cell proliferation which was no longer affected by 
TGF-β isoforms. PTEN overexpression in PC3 cells inhibited cell proliferation. 
Knockdown of endogenous PTEN enhanced cell migration in DU145 cells, whereas 
PTEN overexpression reduced migration in PC3 cells and reduced phosphorylation of 
AKT in response to TGF-β. Based on these results, we conclude that PTEN plays a role 
in inhibitory effects of TGF-β on cell proliferation whereas its absence may enhance 
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Prostate cancer is the most common malignancy among men in the United States. 
According to cancer statistics, there will be an estimated 161,360 new cases diagnosed 
and 26,730 deaths in 2017, which represent 19% of all cancer cases and 8% of cancer-
related deaths among American men, respectively (Figure 1).1 Well established risk 
factors for prostate cancer include age, race/ethnicity, family history of the disease, and 
certain inherited genetic conditions.2 In black men, the risk of prostate cancer is 74% 
higher than whites for reasons that remain unclear, but may include inherited 
susceptibility.3 Overall, prostate cancer death rate has been decreasing in men of all races 
and ethnicities by about 3% per year since 1999, although death rates remain more than 
twice as high in black men compared to any other group of men.3 Men diagnosed with 
local or regional prostate cancer have almost a 100% 5-year survival rate, however, men 
diagnosed with prostate cancer that has spread to other parts of the body have a 5-year 
survival rate of only 29% 4 This decrease in survival due to metastasis is cause for 
ongoing research in the area of invasion and metastasis. 
Transforming growth factor-β (TGF-β) is a secreted cytokine and a major 
regulator of many cellular processes implicated as factors in cancer formation and 
progression such as proliferation, survival, migration/invasion and metastasis.5 TGF-β 





Figure 1. 2017 Estimates for leading cases and deaths in the United States. 
Image taken from American Cancer Society (2017).3 
 
stages of many cancers and while in later stages of many cancers, it exerts prooncogenic 
roles promoting epithelial to mesenchymal transformation (EMT) which converts static 
epithelial cells into highly invasive mesenchymal cells, a necessary pre-requisite for 
tumor cell metastasis. 6–8  The three TGF-β isoforms, TGF-β1, TGF-β2, and TGF-β3 
have been identified in mammalian cells and share a 70%-80% sequence homology in 
most organisms and play redundant roles in cancer cells. 9–11 Although TGF-β1 is the 
most commonly studied TGF-β isoform concerning TGF-β signaling and function, and is 
ubiquitously expressed among cell lines and in cancer,12,13 all three isoforms bind to the 
same receptors and exert similar biological effects on target cells.9,14 These isoforms 




(TGF-βRI) which recruit and phosphorylates receptor associated- Smads (R-Smads), 
Smad 2 and Smad 3. These phosphorylated R-Smads (Smad 2 and -3) then form 
heterodimeric complexes with Smad 4 that are then translocated into the nucleus where it 
functions to regulate responses.10,15 While it has been shown that all three TGF-β 
isoforms signal by binding TGF-βRII and TGF-βRI, it has been suggested that TGF-β1 
and TGF-β3 share a similar receptor binding affinity to TGF-βRII and can exert similar 
biological effects on target cells, however TGF-β2 differs in that it binds to TGF-βRII 
with an affinity that is 100-1,000 fold lower and requires TGF-β Receptor III (TGF-
βRIII) (betaglycan) to promote  receptor assembly with TGF-β2.9,16,17 
 It has been shown in earlier studies that TGF-β isoforms can differentially 
regulate cancer during different stages of the disease. For instance, evidence indicates 
that TGF-β1 is frequently overexpressed in carcinoma cells, including prostate cancer 
cells, and leads to paracrine stimulation and modification of cellular and extracellular 
matrix components of the tumor microenvironment.18,19 TGF-β2 has been shown to 
confer resistance to TNFα-induced apoptosis in prostate cancer cells.15,20 It has also been 
demonstrated that TGF-β3 increased the invasiveness of endometrial carcinoma cells via 
a Phosphatidylinositol-3 Kinase (PI3-kinase) –dependent pathway, which were distinct 
from TGF-β1.21,22 TGF-β3 expression has been previously studied in a variety of human 
cancers, including prostate cancer 9,23,24. Our laboratory has shown TGF-β effects on 
migration and invasion of prostate cancer cells, and these effects are dependent on both 
TGF-βRI and Smad3, and are mediated via the PI3-kinase pathway 9.Moreover, TGF-β1 




cell lines. Both isoforms inhibit proliferation in DU145 cells; however, PC3 cells do not 
respond to the inhibitory effects of either of the two isoforms,9,25–27 which indicates TGF-
β differential effects on cell proliferation depending on the context of the cell. 
Previous evidence has clearly suggested the involvement of the PI3-kinase 
signaling pathway mediating TGF-β effects on cancer cell invasion and metastasis.9,28,29 
PI3-kinase has been shown to regulate diverse cellular processes such as metabolism, 
survival, proliferation, apoptosis, growth, and cell migration in both normal and diseased 
tissues.30,31  It has been demonstrated that TGF-β can rapidly induce PI3-kinase activation 
as determined by increased phosphorylation of AKT, a downstream target of PI3-kinase, 
to promote EMT, cell migration and survival.32–35 Furthermore, one study indicated that 
mechanistically, the PI3-kinase regulatory subunit, p85, appears to be constitutively 
bound to the TGF-βRII and, upon TGF-β stimulation, TGF-βRI is recruited to the 
complex activating PI3-kinase to initiate signaling downstream.36 
The PI3-kinase/AKT signaling pathway is negatively regulated by phosphatase 
and tensin homolog (PTEN), a tumor suppressor, through its lipid phosphatase activity by 
dephosphorylating phosphatidylinositol-3,4,5-triphosphate (PIP3) to phosphatidylinositol- 
4, 5-bisphosphate (PIP2), and therefore counteracts cell survival mechanism elicited by 
this signaling.30,37 PTEN is deleted or mutated in a variety of human cancers, including 
prostate cancer, 38,39 allowing for the increase in PIP3 level fueled by PI3-kinase that in 
turn allosterically activate AKT protein kinase.40–42 Activating mutations of the PI3-
kinase pathway and loss of PTEN are extremely common in advanced cancer tumor 




led to higher basal levels of phosphorylated AKT (pAKTser473) and increased survival of 
cells.43–45 A recent report has confirmed that an isoform-specific role of TGF-β in 
migration and invasion of  metastatic PC3 prostate cancer cells, which are dependent on 
the activation of the PI3-kinase pathway, but did not see similar effects of TGF-β 
isoforms on the activation of PI3-kinase and pAKT in DU145 prostate cancer cells.9 This 
suggests that one possible contributor of differential effects of TGF-β on the activation of 
PI3-kinase may be PTEN. PTEN is expressed in the DU145 prostate cancer cell line, but 
the gene is deleted in PC3 cells which lack PTEN expression.46–49 Another study 
indicated that the loss of PTEN expression in human cancers may contribute to a role for 
TGF-β as a tumor enhancer with specific effects on cellular motility and invasion.50  
Although previous studies confirmed an isoform-specific role of TGF-β on 
migration and invasion of metastatic prostate cancer cells which are dependent on the 
activation of the PI3-kinase pathway, the role of PTEN in TGF-β effects on the activation 
of PI3-kinase in prostate cancer cells has yet to be elucidated. Therefore we hypothesize 
that PTEN may play a role in TGF-β induced effects on cell proliferation, migration, 
invasion, and the activation of PI3-kinase/AKT pathway in prostate cancer cells. 
Furthermore, reports have indicated that PTEN activity is regulated by multiple post-
translational mechanisms,51,52 however, the role of TGF-β in the regulation of PTEN 
activity in prostate cancer have not been investigated. To test this hypothesis, the 
following aims were investigated: 
1. To determine the expression of PTEN and pAKT in prostate cancer cells, and 




2. To determine the role of PTEN in TGF-β on the activation of PI3-kinase/AKT 
pathway, proliferation, migration, and invasion. 







REVIEW OF THE LITERATURE
2.1 The Prostate 
 The prostate gland is an exocrine organ of the male reproductive system located 
in the pelvic cavity.53 Its secretes the prostatic fluid that is slightly acidic (pH of ~6.4) 
that forms 20% (by volume) of the semen.53 The location of the prostate gland is 
posterior to the lower portion of the symphysis pubis, anterior to the rectum, and inferior 
to the urinary bladder in the subperitoneal compartment between the pelvic diaphragm 
and the peritoneal cavity (Figure 2A).54 The prostate is enveloped by a thin fibromuscular 
layer divided into three zones which are the transition zone, central zone, and the 
peripheral zone (Figure 2B).55 These zones produce and drain prostatic secretions into the 
urethra, account for approximately 70% of the total prostate bulk with the fibromuscular 
stroma, comprising of connective and smooth muscle, making up the remaining 30%.56 
Testosterone, the primary androgen is produced by the testes; in peripheral tissues such as 
the prostate, testosterone is converted locally to dihydrotesterone (DHT) by the action of 
the enzyme 5α- reductase.56,57 DHT is more potent than testosterone and has a higher 
affinity for the nuclear androgen receptor.56,58 Various mechanisms can activate the 
androgen receptor which results in cell proliferation and cell growth.59 Growth factors 
such as TGF-β and EGF are expressed by prostate cells during prostate development. In 
non-diseased prostate, TGF-β is believed to play a role in regulating cell growth through 
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its anti-proliferatory effects due to the ability to inhibit the mitogenic effects of 
EGF/TGF-α on epithelial cells60 and of basic FGF (bFGF) on stromal cells.61 
Furthermore, prostate fluids, from non-diseased human prostates, contain large amounts 




Figure 2. The adult prostate and surrounding structures.  
(A) The prostate gland is located below the bladder. The urethra runs through the center 
of the prostate, from the bladder to the penis. Image is taken from 
http://www.healthhype.com/tips-for-living-with-a-large-prostate.html.64 (B) The prostate 
divided into three zones which are transition zone, central zone, and the peripheral zone. 
Image is taken from Toivanen and Shen (2017).55  
 
2.2 Prostate Cancer 
Prostate cancer is the second leading cause of cancer deaths among men 
especially in the United States and in all racial groups. Although older age and family 
history are risk factors for being diagnosed with prostate cancer, race/ethnicity is a strong 
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risk factor especially among African American men. In 2017, according to the American 
Cancer Society, 161,360 men will be diagnosed, and 26,730 will die of prostate cancer.3 
Early stages of prostate cancer are located in the prostate gland, where they are more 
easily cured by surgery and radiation therapy. However, in later stages, prostate cancer 
metastasizes to secondary sites, usually in the bone, lung, or liver.21 The standard of care 
for treating metastatic prostate cancer is hormonal therapy and chemotherapy. Hormonal 
therapies are aimed at the inhibition of the production or activity of androgens.21 Prostate 
cancer cells in advanced stages become resistant to hormonal therapy treatments, which 
results in castration-resistant prostate cancer.22 Currently, there is no effective treatment 
or preventative option for advanced stage androgen-independent prostate cancer. Thus, 
the development of therapeutic strategies targeting the development or progression of 
metastatic prostate cancer will lead to increased survival of prostate cancer patients. More 
recently, prostate cancer has been shown to exhibit a racial disparity among African 
American men, and the  incidence of mortality rates for African American men are 1.5 
and 2.3 times higher than for Caucasian men 65 and even higher compared with all non-
African-American men, respectively.66 Many explanations for health disparities have 
attributed them to modifiable factors such as low socioeconomic status and lack of access 
to health care; however, when such factors are controlled for, factors may include 
biological and/ or genetic differences.65,67 Previous studies demonstrated that TGF-β1 is 
hyperexpressed frequently in African Americans men compared to Caucasians.68 A 
recent study reported that peripheral blood TGF-β1 protein levels are positively 
associated with plasma renin activity, systolic blood pressure, diastolic blood pressure, 
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body mass index, metabolic syndrome, and microalbuminuria are more predictive in 
African Americans but not in whites. 68,69  Furthermore, the overexpression of TGF-β1 
was significantly more frequent in African American patients with hypertension,68,70 end-
stage renal disease,68,71,72 diabetes,73 and glaucoma.74 
 Major processes and molecular events are believed to represent important 
contributing factors in prostate carcinogenesis and have been associated with possible 
roles in cancer initiation and progression. These events include inflammation, oxidative 
stress, DNA damage, genetic factors, tumor suppressor/ promotor genes, growth factor 
production, and receptor signaling. Of these molecular mechanisms, the tumor suppressor 
gene, PTEN, is frequently mutated or deleted in many cancers, including prostate.43 
PTEN negatively regulates the PI3-kinase pathway and considerable evidence indicates 
that PTEN loss of function results in up-regulation of the PI3-kinase/AKT/mTOR 
signaling pathway in prostate cancer, primarily through the activation of AKT. 75–78 In 
addition to the PI3-kinase signaling pathway and its involvement in prostate cancer, 
members of the TGF-β superfamily also play important roles in the progression of cancer. 
TGF-β exhibits tumor suppressor activities in the early stages of epithelial cancers. 
However, in the later stages of disease, TGF-β acts as a tumor promoter and is associated 
with aggressive form of cancers due to its effects on angiogenesis, immune suppression, 
and metastasis.28,79 Identifying differences in the effects of TGF-β superfamily on cellular 




2.3 Metastasis  
 The complex process of metastasis remains the main cause for cancer related 
deaths. It involves the progression from the primary tumor development to the expansion 
of tumor cells at the secondary site of metastasis. Since the metastatic cascade involves 
many complex steps, generally it is considered to be an inefficient process.80 Although, 
common sites of secondary metastasis for prostate cancer are lung, liver, and pleura, in 
prostate cancer metastasis, it invariably goes to bone, forming characteristic osteoblastic 
lesions.81–83 
Many different stages of metastatic progression have been hypothesized which 
include tumorigenesis, dissemination and expansion of tumor cells at the secondary site. 
Mechanisms such as microRNAs, germline polymorphisms and the tumor 
microenvironment combined explain the metastatic cascade.  
 A critical process during tumor invasion and metastasis, as well as embryonic 
development, is the epithelial-mesenchymal transition (EMT). EMT occurs when 
epithelial cells lose or modify their apical-basal polarity and are converted to a 
mesenchymal phenotype.84,85 During metastasis, EMT disrupts the intercellular tight 
junctions and promotes migration, and self-renewing and stem-like properties to facilitate 
metastatic colonization.86,87 In this process, single tumor cells dissociate from the primary 
tumor, adopt mesenchymal properties to invade into the blood stream, and  after 
extravasation circulating tumor cells (CTCs) regain epithelial characteristics, thus they 
can seed in secondary tissues, forming a metastatic bud (mesenchymal to epithelial 
(MET)) (Figure 3).88 EMT is influenced by the microenvironment and has been observed 
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primarily at the tumor-stromal interface.84,89 EMT is commonly characterized by the 
suppression of the cell-cell adhesion receptor E-cadherin and endows cells with more 
motile, invasive properties.87,90 Extracellular matrix metalloproteinases (MMPs) can 
degrade the cell basal lamina and extracellular matrix (ECM), and these enzymes 
maintain a balance with tissue inhibitors of metalloproteinases, which play vital roles in 
the invasion and metastasis of malignant tumors.91–93 Furthermore, the distinct features of 
EMT in tumor progression are also initiated and maintained by members of the TGF-β 
family of growth factors, activating major signaling pathways and transcriptional 
regulators integrated in the extensive signaling networks.90 
 
 
Figure 3. Remote metastasis formation.  
Circulating tumor cells (CTCs) undergoing epithelial to mesenchymal transition-





2.4 Transforming Growth Factor-β (TGF-β) 
 Transforming growth factor-β (TGF-β), a multifunctional polypeptide, is a 
member of a large family of cytokines that regulate many aspects of cellular function, 
including mammalian development, cellular proliferation, differentiation, homeostasis, 
migration, apoptosis, adhesion, angiogenesis, immune surveillance, and survival. These 
signaling consequences of TGF-β are dependent on factors including cell type, growth 
conditions and the presence of other growth factors.  
 The TGF-β superfamily is composed of more than 30 proteins in humans 
including TGF-β isoforms, activins, nodal, and bone morphogenetic proteins (BMPs). 
Activins, nodal, and BMPs play important roles in early embryogenesis;94–97 activins 
induce dorsal mesoderm in (Xenopus) embryos, whereas BMPs induce ventral mesoderm 
and also play critical roles in morphogenesis of various tissues. 97  Nodal inhibits 
differentiation, maintains the pluripotency of human embryonic stem cell (hESCs), and 
promotes the self-renewing capacity of mouse ES cells.97,98 The highly similar TGF-β 
isoforms TGF-β1, TGF-β2, and TGF-β3 potently inhibit cellular proliferation of many 
cell types, including those from epithelial origin, and most mesenchymal cells are 
stimulated in their growth by TGF-β.12  Many growth factors belonging to the TGF-β 
superfamily play important roles in embryonic development. These growth factors may 
also play more crucial roles at relatively late stages of development and in adult tissues.97 
2.5 TGF-β Signaling Pathway 
The canonical TGF-β signaling pathway involves three types of receptors which 
are type I, II, and III. There are seven members of the type I receptor (TGF-βRI) family 
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which include activin receptor-like kinase (ALK) (1–7), and five known members of the 
type II receptor (TGF-βRII) family have been characterized in mammals including TGF-
βRII, activin receptor II and IIB (ActRII, ActRIIB), bone morphogenic protein receptor II 
(BMPRII), and anti-Müllerian hormone receptor 2 (AMHRII).12,97,99 The TGF-β ligand 
signals through the TGF-βRII and the ALK5 complex in most cells.12,25 The type III 
receptor (TGF-βRIII), also known as betaglycan, and the related molecule endoglin, act 
as enhancers of growth factor access to corresponding signaling receptors.100  The 
initiation of TGF-β signaling involves the binding of TGF-β ligands to its (serine and 
threonine) kinase receptors which are TGF-βRII and TGF-βRI located on the cell 
membrane. Ligand binding leads to formation of the receptor heterocomplex, in which 
TGF-βRII phosphorylates TGF-βRI and thus activates TGF-βRI (Figure 4).101–103  The 
Smad family consists of eight Smad proteins which are classified into three subgroups: 
receptor- activated Smads (R-Smads) (Smads1, 2, 3, 5, and 8), the common Smad 
(Smad4), and the inhibitory Smads (I-Smads) Smad6 and Smad7.103Activated TGF-βRI 
recruits and phosphorylates R-Smad proteins, which include Smad 2 and Smad 3 for 
TGF-β isoforms and activin, while Smad 1, Smad 5, and Smad 8 are for BMP signaling, 
which leads to the formation of a heterocomplex with their constitutive co-Smad, 
Smad4.101,104,105  This Smad complex is then translocated in the nucleus where it 




Figure 4. The canonical transforming growth factor β (TGF-β) signaling pathway.  
Figure taken from Hui and Friedman (2003). Expert Reviews in Molecular Medicine 
 
2.6 TGF-β Isoforms 
The TGF-β multifunctional cytokines are a family that exerts important roles in a 
variety of effects on normal and transformed cells. TGF-β exist as three mammalian  
isoforms which are TGF-β1, TGF-β2, and TGF-β3.The three isoforms, TGF-β1-3 have 
more than 97% sequences identity in mammalian tissue and signal through activation of 
TGF-β receptors.108,109 It has been revealed that the amino acid sequences of the three 
mammalian TGF-β isoforms share a high level of similarity between the active domains; 
TGF-β3 is 86% similar to TGF-β1, while it shares 91% similarity with that of TGF-β2 
(Figure 5).14 TGF-β2 and TGF-β3 share the highest level of sequence similarity out of the 
three isoforms; however, TGF-β2 binds to the TGF-β receptor II (TGF-βRII) differently 
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from TGF-β1 and TGF-β3 through different residues.110 Both TGF-β1 and TGF-β3 bind 
to type II receptor.100,111,112 Previous studies showed that the soluble extracellular domain 
of receptor II binds TGF-β1 and TGF-β3 with apparent dissociation constants of 200pM 
and 500pM, respectively, but the recognition of TGF-β2 was supported by the presence 
of receptor III,113 which is a membrane-anchored proteoglycan without any apparent 
signaling motif.114,115   
 
 
Figure 5. Amino acid sequence alignments of TGF-β1, TGF-β2, and TGF-β3. 
Figure taken from Laverty et al. (2009).14 
 
 
 TGF-β3 has also been shown to differ significantly from TGF-β1 and TGF-β2 in its 
detailed tertiary structure of the activated domain. According to Nuclear Magnetic 
Resonance (NMR) data show which that alpha helical region of TGF-β1 is structurally 
ordered,116  while the alpha 38 helical region of TGF-β3 is structurally disordered,117,118 
indicating that TGF-β3 adopts a more flexible “open” state in the crystal structure and in 
its complex with TGF-βRII.119,120 Their difference in structural flexibility is that TGF-β1 
may lock the receptor complex in a closed conformation, while TGF-β3 may have a more 
open conformation due to greater flexibility of the TGF-β3 dimer. 14   These observations 
imply that the structures of the ligand/ receptor complexes for TGF-β1 and TGF-β3 may 
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be significantly different and may engage the downstream signaling pathways in different 
ways, which leads to different biological outcomes. 14 
2.7 TGF-β in Normal Development 
TGF-β isoforms are multifunctional cytokines and members of the TGF-β 
superfamily of signaling proteins that are critical for growth, differentiation, control of 
the immunological response, tissue homeostasis, and embryonic development of many 
different cell types within an organism. There have been multiple reports on the critical 
roles for TGF-β isoforms in embryonic development using knockout null-mutant 
mice.121–125 Among cytokines and growth factors, numerous in vivo and in vitro studies in 
various models have shown TGF-β’s leading role in the bone fracture healing process,126–
131 and TGF-β’s involvement in nerve regeneration.132–135 In addition, primary functions 
of TGF-β include enhancing formation of the extracellular matrix, regulation of cellular 
differentiation, and inhibition of proliferation of most cells.121,136,137  Tumor suppressor 
responses of TGF-β are essential for maintaining homeostatic control of normal cell 
growth and cells in early phases of tumorigenesis.138 In premalignant cells, TGF-β act as 
a tumor suppressor of c-Myc expression,139 and the induction of the cell cycle inhibitors 
p15 and p21.138 Studies have suggested that the tumor suppressor response of TGF-β is 
important in the early stages of tumorigenesis. One report showed that activation of TGF-
β delays the appearance of primary mammary tumors, and mice deficient in TGF-β 
signaling are prone to earlier tumor development.140 In contrast, mice expressing an 
activated TGF-β receptor exhibited an increase in metastatic lung foci, which is 
consistent with a pro-oncogenic effect of this pathway in late-stage disease.79,138 
18 
 
Advanced disease is accompanied by increased expression and the activation of TGF-β. 
TGF-β acts as a tumor suppressor in early stages of epithelial cancers by inhibiting 
proliferation and inducing apoptosis.79 However, in later stages of cancer, TGF-β acts as 
a tumor promoter facilitating tumor cell and also targets genes involved in angiogenesis 
and metastasis.79 
2.8 TGF-β Isoforms and Cancer 
 TGF-β has been implicated in cancer formation and progression.  Generally, it has 
been found that there is a marked increase in TGF-β mRNA and protein in human 
cancers (in vivo), including those of the pancreas, colon, endometrium, prostate, breast, 
brain, and bone,141 and in many of these types of cancers high expression of TGF-β 
correlates with advanced stages of malignancy and decreased survival. Among multiple 
cancers, TGF-β plays an important role in the progression of prostate cancer.  It acts as a 
tumor suppressor in the early stages of epithelial cancers by inhibiting proliferation and 
inducing apoptosis.79 However, in later stages of many cancers, the tumor cells become 
resistant to growth inhibitory effects of TGF-β, in which TGF-β acts as a tumor promoter 
due to its role in stimulating angiogenesis, epithelial to mesenchymal transformation, or 
promoting the degradation of ECM due to increased production of MMPs; all of which 
aid invasion and metastasis.9,142–144 Of the three TGF-β isoforms (TGF-β1, TGF-β2, and 
TGF-β3), TGF-β1 is the most commonly studied and tends to be ubiquitously expressed 
among cell lines and in cancer.9,12,13 During the signaling process, TGF-β binds first to 
TGF-βRII and then to TGF-βRI.118 The ectodomain of TGF-βRII binds with higher 
affinity to TGF-β3 than to TGF-β1, whereas the recognition of TGF-β2 has to be 
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supported by the presence of  TGF-βRIII (betaglycan).113,118 It is implicated that both 
TGF-β1 and TGF-β3 share similar sequence homology, receptor binding affinity and 
similar biological effects on target cells, however, they may retain the ability to have non-
redundant differential effects.9 Evidence indicates that TGF-β1 is frequently 
overexpressed in carcinoma cells, including prostate cancer cells, and leads to paracrine 
stimulation and modification of cellular and extracellular matrix components of tumor 
microenvironment.18,19 It has also been demonstrated that TGF-β3 increased the 
invasiveness of endometrial carcinoma cells via a PI3-kinase-dependent pathway, which 
were distinct from TGF-β1.29 In several different cancers, TGF-β3 expression levels have 
been reported from clinical studies. For instance, an earlier study indicated in colon 
carcinoma biopsies that the expression of TGF-β3 was uniform across tissue stages as 
well as normal tissue samples, suggesting that the isoform is unlikely to play a role in 
cancer progression.145 However, in breast carcinomas, clinical studies reported an 
increase in TGF-β3 expression, which correlated with a decrease in overall survival.146,147 
TGF-β3 expression has also been studied in prostate cancer. One study revealed that 
TGF-β3 expression increases 2 fold in prostate tumors.148 Furthermore, our laboratory 
has shown that TGF-β effects on migration and invasion of prostate cancer cells are 
primarily induced by TGF-β3 and that those effects are dependent on both TGF-β 
receptor I and Smad3 and mediated via the PI3-kinase pathway.9 
2.9 The Phosphatidylinositol 3-Kinase (PI3-Kinase) Signaling Pathway 
 The phosphatidylinositol 3-kinase (PI3-kinase) pathway regulates diverse cellular 
processes such as metabolism, survival, proliferation, apoptosis, growth, and cell 
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migration. PI3-kinase is a family of lipid kinases that phosphorylate the 3’ –hydroxyl 
group of phosphatidylinositols and phosphoinositides.149 PI3-kinase is divided into three 
classes which show distinct substrate specificity: Class I (IA and IB), Class II, and Class 
III. Class I PI3-kinase isoforms are mostly studied and understood in mammalian cells 
and represent important druggable targets for multiple human diseases.150 Notably, Class 
IA PI3-kinase is activated by receptor tyrosine kinases (RTKs), whereas Class IB PI3-
kinase are activated by G-protein coupled receptors (GPCRs), in which both RTKs and 
GPCRs are stimulated by growth factors and hormones.150 Class IA PI3-kinase is a 
heterodimeric signaling factor composed of a regulatory subunit (p85α/β) and a catalytic 
subunit (p110α/β/γ/δ), which upon activation converts phosphatidylinositol -4,5-
bisphosphate (PIP2) to phosphatidylinositol – 3, 4, 5- triphosphate (PIP3) (Figure 6).
149,151 
PIP3 transduces activating signals by binding to the pleckstrin homology (PH) domains of 
protein, thereby recruiting them to the membrane.149,152 AKT (also known as protein 
kinase B), is a serine-threonine kinase that is an important downstream effector of PIP3, 
in which AKT is recruited to the membrane via PIP3 binding of its PH domain and is 
phosphorylated either by PDK1 (3-phosphoinositide-dependent kinase),149 at threonine 
308,153 and at serine 473 by the rapamycin-insensitive mTOR complex (mTORC2)154  or 
potentially by other kinases in some contexts.155  The PI3-kinase/AKT signaling pathway 
is negatively regulated by PTEN (phosphatase and tensin homolog deleted on 
chromosome 10), a tumor suppressor, by dephosphorylating PIP3 to PIP2, and therefore 
counteracts cell survival mechanisms elicited by this signaling.30,37  
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AKT is a signaling pathway that is activated downstream of PI3-kinase, and has 
attracted much attention because of its role in cell survival.30 The PI3-kinase/AKT 
pathway provides a mechanism in cancer progression which includes evading cell death 
pathways. AKT promotes cell survival and may regulate cell proliferation by means of 
phosphorylation of multiple targets. There are three isoforms of AKT encoded by three 
different genes which include AKT1, AKT2, and AKT3, and these isoforms are of the 
serine/threonine protein kinase B family.30,156 It has been reported that AKT1 and AKT2 
have been found to be overexpressed in gastric adenocarcinomas; breast cancers, ovarian 
cancers, and pancreatic cancer; while studies have indicated that AKT3 may contribute to 
breast and prostate carcinoma.157–160 It has also been reported that levels of HIF-1α 
(Hypoxia-induced factor-1α) are controlled by  
 
Figure 6. Schematic representation of the PI3-Kinase/AKT signaling pathway. 
Image taken from Meier et al. (2005).161 
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PI3-kinase and represent a critical component in AKT-dependent angiogenesis and 
tumorigenesis.162 High levels of phosphorylated AKT (pAKT), which is activated AKT, 
is correlated with poor prognosis of prostate cancer, whereas in normal prostate tissue, 
pAKT is undetectable.163 
2.10 Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), is a well-
known tumor suppressor located in the 10q23 region of chromosome 10 encoding for a 
403-amino acid multifunctional protein, which possesses both lipid and protein 
phosphatase activities.164 PTEN plays a role in regulating a number of cellular processes, 
including cell death and proliferation, through the PI3-kinase/AKT/mTOR pathway. 
Evidence suggests that the tumor suppressor status of PTEN relies on its normal cellular 
activity as a lipid phosphatase which reduces the cellular levels of PIP3 
165,166 
(dephosphorylating PIP3 to PIP2), and negatively regulate the PI3-kinase/AKT signaling 
pathway, thereby antagonizing downstream activity controlled by the AKT/mTOR axis, 
such as cell cycle progression, induction of cell death, transcription, translation, 
stimulation of angiogenesis, and stem cell self-renewal. 152,167–173  In addition to its ability 
to dephosphorylate lipid substrates, PTEN also exhibits protein phosphatase activity, 
responsible for some of its biological effects including inhibition of cell migration and 
cell cycle arrest. 174,175  
The PTEN tumor suppressor gene is most frequently lost, either partially or fully 
from sporadic human tumor types, and with germline mutations causing-predisposition 
syndromes such as Cowden and Bannayan- Zonana syndromes.176–179 Mutations in PTEN 
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have been found in a variety of human tumors occurring in about 50% of glioblastoma, 
endometrial carcinoma, prostate carcinoma, bladder carcinoma, and melanoma 
cases.176,180,181 During tumor development, PTEN mutations, and deletions often occur 
that inactivate or decrease PTEN function, and loss of PTEN can also occur by epigenetic 
silencing, transcription, or disruption of competitive endogenous RNA (ceRNA) 
networks.176,179 More than a decade of research has demonstrated and expanded our 
knowledge on the role of PTEN in cancer. Previous experiments performed in transgenic 
mice have revealed that loss of both copies of the PTEN gene resulted in embryonic 
lethality, whereas PTEN heterozygous mutants develop a diverse range of dysplasias in a 
wide spectrum of tissues with high incidence of prostate and colon cancer.182,183  
Furthermore, recent studies demonstrated a dose-dependent role of PTEN in cancer 
which highlighted that subtle reductions in active PTEN levels dictate cancer 
susceptibility.184,185  The dysfunction of PTEN plays crucial roles in the pathogenesis of 
hereditary and sporadic tumors. In addition to genomic inactivation, many other 
pathogenic mechanisms are associated with PTEN’s gene expression or subcellular 
compartmentalization of the protein associated with tumorigenesis. PTEN’s activity can 
indeed, be modulated by mutations, epigenetic silencing, transcriptional repression, post-
transcriptional regulation, aberrant protein localization, protein-protein interaction, and 
post-translational modifications.164,186 These mechanisms are known to regulate, and fine-
tune PTEN’s expression and function.  
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2.11 TGF-β and the PI3-Kinase/AKT/PTEN Signaling Pathway  
There have been numerous studies that suggest a role for TGF-β in PI3-kinase 
signaling. Reports have indicated that TGF-β can activate the PI3-kinase pathway as 
determined by increase in the phosphorylation of AKT.32–35,187 Although it has yet to be 
elucidated on how TGF-β activates the PI3-kinase pathway, studies have revealed that 
activation of AKT can be independent of Smad2/3 and that both TGF-βRI and TGF-βRII 
kinase activity associates with the p85 subunit of PI3-kinase protein, therefore activating 
the pathway.32,33,35,36,188 It has also been implicated that PI3-kinase/AKT signaling is 
required for TGF-β induced transcriptional responses, EMT, and cell migration. 32 
Previous evidence has suggested the involvement of PI3-kinase pathway in TGF-β 
mediated effects on cancer cell invasion and metastasis 9,28 and that the effects of TGF-β 
isoforms on cell migration and invasion are mediated by both TGF-βRI and Smad3 
dependent activation of the PI3-kinase pathway.9 Activating mutations of the PI3-kinase 
pathway and loss of PTEN are extremely common in advanced cancer and are associated 
with tumor progression.43 An earlier study indicates that the loss of PTEN expression in 
human cancers may contribute to a role for TGF-β as a tumor enhancer with specific 
effects on cellular motility and invasion.50 Another study showed that TGF-β signaling is 
induced in the prostate by PTEN loss or by activation of AKT, and functions to keep in 
check the tumorigenic effects of PI3-kinase/AKT pathway activation.189 Whether or not 
PTEN plays a role in TGF-β effects on the activation of PI3-kinase in prostate cancer has 





3.1 Chemicals and Reagents 
Recombinant human TGF-β1 and TGF-β3 were purchased from PeproTech 
(Rocky Hill, NJ). Mammalian expression vectors pcDNA3 GFP PTEN (plasmid # 
10759), and pcDNA3 GFP (plasmid #20738) were obtained from Addgene (Cambridge, 
MA). Human PTEN siRNA (sc-29459) and control non-silencing siRNA (sc-37007) 
were purchased from Santa Cruz Biotechnology (Dallas, TX). Matrigel, rat tail collagen 
and transwell inserts were purchased from BD Biosciences (Bedford, MA). DAPI (4’, 6-
Diamidine-2-phenylindole dihydrochloride) was purchased from Roche Diagnostics, 
(Indiana, IN). The antibodies against PTEN, pAKTSer473, AKT (pan), pSmad2, pSmad3, 
and Smad2/3 were purchased from Cell Signaling Technology (Danvers, MA). Antibody 
against pPTENSer380 was purchased from Santa Cruz Biotechnology (Dallas, TX). 
Antibody against β-Actin (clone AC-15) was purchased from Sigma-Aldrich (St. Louis, 
MO).  Goat anti-rabbit IgG HRP was obtained from Life Technologies (Grand Island, 
NY). Anti-mouse IgG HRP was obtained from GE Healthcare (Piscataway, NJ).  
3.2 Cell Lines and Cell Culture 
Prostate epithelial and prostate cancer cell lines were obtained from American 
Type Culture Collection (ATCC) (Rockville, MD), which include RWPE1 (immortalized 
human prostate epithelial cell line) 190, and prostate cancer cell lines isolated from distinct 
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metastatic sites from prostate cancer patients such as androgen-dependent cell line 
LNCaP (derived from a lymph node lesion), and androgen-independent cell lines DU145 
(derived from brain) and PC3 (derived from bone) (Table 1).191 RWPE1 cells were 
maintained in keratinocyte serum free medium containing 50µg/ml gentamycin, 
0.05mg/ml bovine pituitary extract (BPE), and 5ng/ml epidermal growth factor (EGF) 
(Invitrogen, Carlsbad, CA). LNCaP cells were maintained in RPMI-1640 medium 
containing 4mM L-glutamine, and 50µg/ml gentamycin. DU145 and PC3 cells were 
cultured in Eagles minimum essential medium with Earle’s salts with 0.1 mM of the 
following amino acid supplements: L-alanine, L-asparagine, L-aspartic acid, L-glutamic 
acid, L-proline, L-serine, and L-glycine. The medium contained 4 mM L-glutamine, 2.5 
g/l NaHCO3, 1.5 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml 
amphotericin B and 50 µg/ml gentamycin. MEM and RPMI media (Mediatech, Herndon, 
VA) were supplemented with 5% fetal bovine serum (HyClone, South Logan, Utah). 
3.3 RNA Isolation, cDNA Synthesis, and RT-PCR 
 
Total RNA was isolated from normal prostate and prostate cancer cells using 
TRIzol (Invitrogen, Carlsbad, CA). The RNA samples were quantified by optical density 
reading at 260nm as described previously 192; OD260/OD280 ratio for RNA samples 







Table 1. The Origins of the Cell Lines Used 
 
 
mixture containing 0.5 mM dNTP (Fisher Scientific, Pittsburgh, PA), 0.5 mM 
dithiothreitol (Bio-Rad, Hercules, CA), 0.5 µg of oligo dT,  and 400 U of M-MLV 
Reverse Transcriptase (Promega, Madison, WI) at 37°C for 1.5 hours.  The reaction was 
terminated by heating the samples at 60°C for 5 min and subsequently cooled to 4°C. 
Polymerase chain reaction (PCR) was performed to detect mRNA levels of PTEN and L-
19. The sequences of primer pairs that were used are as follows:  human PTEN (forward 
5’AGCTTCTGCCATCTCTCTCC-3’ and reverse 
5’AATATTGTTCCTGTATACGCCTTC-3’) and L-19 (forward 
5’GAAATCGCCAATGCCAACTC-3’ and reverse 5’TCTTAGACCTGCGAGCCTCA-
3’). RT-PCR reactions were performed according to procedures described previously 193.  
L-19 (a ribosomal protein) was used as an internal control. The PCR products were 





3.4 Quantitative RT-PCR (qRT-PCR) 
The mRNA levels of PTEN were determined by quantitative RT-PCR. Total RNA 
isolation and cDNA synthesis of DU145 cells are described previously.97 The quantitative 
RT-PCR was performed with iCycler (Bio-Rad, Hercules, CA, USA) in 96-well plates. A 
SYBER-Green Master Mix (Bio-Rad) was used in a volume of 25µl/well 97. The 
following primers were used: human PTEN (forward 
5’CGACGGGAAGACAAGTTCAT-3′ and reverse 5’AGGTTTCCTCTGGTCCTGGT-
3′) and GAPDH (forward 5’GAAGGTGAAGGTCGGAGTC-3’) and reverse 
5’GAAGATGGTGATGGGATTTC-3’). Relative quantification of PTEN mRNA 
expression was determined using the 2-ΔΔCT method 194 with GAPDH as an internal 
control. 
3.5 Cell Treatments 
 
To determine the effects of TGF-β isoforms on PTEN, pAKTSer473, pSmad2, and 
pSmad3, cells were cultured in 6 well plates at a density of 2 x 105 cells/well in culture 
media with 5%FBS and allowed to attach overnight. Before each experiment, the cells 
were incubated in serum free or supplement free media for 2 hours, followed by 
treatment with TGF-β1 or TGF-β3 (5ng/ml) over various time points.  Cells were washed 
with ice-cold phosphate-buffered saline (PBS) and lysed in lysis buffer (Cell Signaling 
Technology, Beverly, MA) containing 20mM Tris-HCL (pH 7.5), 150mM NaCl, 1mM 
Na2 EDTA, 1mM EGTA,  1% Triton, 2.5mM sodium pyrophosphate, 1mM β-
glycerophosphate, 1mM Na3VO4, 1µg/ml leptin and 1X protease inhibitor cocktail 
(Calbiochem, La Jolla, CA). Protein concentrations were determined by the Lowry HS 
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assay using the Bio-Rad DC Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, 
CA). 
3.6 Western Blot Analysis 
Cell lysates (35-50µg protein) were subjected to SDS-PAGE in 8% or 10% gels 
and transferred to PVDF membranes (Millipore, Billerica MA). The membranes were 
blocked in 5% fat-free skim milk in TBST (50mM Tris, pH 7.5, containing 0.15M NaCl, 
0.05% Tween 20) for 1 hour at room temperature. The blots were then incubated 
overnight at 4ºC in TBST containing 5% bovine serum albumin (BSA) with appropriate 
dilutions of specific primary antibodies (1:1000 dilution for anti-PTEN; anti-pAKTSer473 , 
anti-Total AKT (pan), anti-pPTENSer380 , anti-pSmad2, anti-pSmad3, anti-Total Smad2/3; 
1:5000 dilution for anti-β-Actin). After washing, blots were then incubated with anti-
rabbit or anti-mouse IgG-HRP (dilution 1:20,000) in blocking buffer (TBST with 1% 
milk) for 1 hour and washed in TBST for 1 hour. The blots were developed in Millipore 
Luminata Forte (EMD Millipore, Billerica, MA) for 5 minutes, exposed by using 
Syngene PXI 6 imaging system (Syngene, Frederick, MD). The density of specific 
protein bands was determined by ImageJ Software (NIH ver1.48) for normalization of 
data. 
3.7 Transwell Cell Migration Assay 
In vitro cell migration assay was performed using a 24-well plate transwell inserts 
(8 µm) as previously described.195 Cells were washed with MEM and harvested from cell 
culture dishes by EDTA-trypsin into 50 ml conical tubes.  The cells were centrifuged at 
1000 RPM for 3 min at room temperature; the pellets were resuspended in MEM 
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supplemented with 0.2% bovine serum albumin (BSA) at a cell density of 3 x 105 
cells/ml. The outside of the transwell insert membrane was coated with 50 µl total 
volume.  Chemoattractant solutions were made by diluting TGF-β1 and TGF-β3 
(5ng/ml), and EGF (10 ng/ml) in MEM for DU145 and PC3 cells, and RPMI for LNCaP 
cells supplemented with 0.2% BSA. MEM containing 0.2% BSA served as a negative 
control. EGF was used as a positive control.196 The results were expressed as migration 
index defined as the average number of cells per field for test substance/the average 
number of cells per field for the medium control.193 
3.8 Invasion Assay 
The invasive properties of DU145 cells were measured using the BD BioCoat 
Matrigel Invasion inserts. Inserts were coated with 50µl of a 1:4 Matrigel/medium 
dilution and allowed to solidify at 37 ͦ C for 48 hours. Cells were resuspended (3 x 104 
cells/ml) in MEM with 0.1% FBS and 500µl of cell suspension were added to each insert. 
Cells were treated with TGF-β1 and TGF-β3 (5ng/ml), or EGF (10ng/ml) and were 
allowed to invade through the porous membrane coated with Matrigel for 48 hours. 
Matrigel and non-invading cells were removed via cotton swabs. Invading cells on the 
membrane were fixed in 3.7% paraformaldehyde and stained using DAPI (Roche 
Diagnostics, Indiana, IN).  Images were taken in five different fields for average number 
invading cells. The results were expressed as invasion index defined as: the average 





3.9 Cell Proliferation Assay 
The cell growth assay was performed by counting the total number of cells. Cells 
were seeded at a density of 1 x 105 cells overnight in 6 well plates and treated the next 
day with TGF-β1 or TGF-β3 (5ng/ml) in culture media containing 1% FBS for specific 
time points. Cells were then trypsinized and counted using the Cellulometer Vision 
System (Nexcelom Bioscience LLC, Lawrence, MA). 
3.10 Transfection with Specific Plasmids and Small Interfering (si) RNAs 
Cells were seeded at a density of 1 x105 cells in 6 well plates in 2ml of antibiotic-
free normal growth medium supplemented with 5% FBS and incubated overnight at 
37ºC. Plasmids (pcDNA3 GFP or pcDNA3 GFP PTEN (PTEN promoter T7 
polymerase)) were transfected in PC3 cells using FuGene® HD transfection reagent 
(Promega, Madison, WI) following manufacturer’s instructions. Small interfering RNA 
(siRNA) (60nM) for the PTEN or Control siRNA were transfected into DU145 cells 
using transfection reagent (Santa Cruz Biotechnology, Dallas, TX) following 
manufacturer’s recommendations. Forty-eight to seventy-two hours after transfection, 
cells were either treated with TGF-β1 or TGF-β3, or subjected to different functional 
analyses. 
3.11 Statistical Analysis 
 
All experiments were performed at least three times using different cell 
preparations. Data from representative experiments are presented in the figures. One-way 
analysis of variance and Duncan’s all pair-wise multiple comparison tests were employed 
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to assess the significance of differences among treatment groups. SigmaPlot version 11.0 





4.1 Expression of PTEN in Prostate Cell Lines 
Gene expression of PTEN in prostate cells was determined using semiquantitative 
RT-PCR across four established prostate cell lines (RWPE1, LNCaP, DU145, and PC3). 
PTEN mRNA was detectable in three of the four cell lines with no detectable expression 
in PC3 cells (Figure 7). 
 
 
Figure 7. mRNA expression of PTEN in prostate cell lines.  
RT-PCR was performed using total RNA from RWPE1, LNCaP, DU145, and PC3 cells 
to determine mRNA levels of PTEN. L-19 served as a loading control and was used to 
normalize mRNA levels in all cell line samples. No reverse transcriptase (RT) samples 
derived from the same RNAs were also included.  
 
To examine the presence of PTEN protein and pAKTSer473 in these cell lines, the 
total cell lysate proteins were analyzed using Western blotting (Figure 8). PTEN protein 
was detected in RWPE1 and DU145 cells, however, it was absent in LNCaP and PC3 
cells (Figure 8A). LNCaP cells, which contain a deactivating frameshift mutation in the 
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gene encoding PTEN 197, and PC3 cells, due to the homologous deletion of both PTEN 
gene, do not express PTEN protein.198 The pAKTSer473 bands were detected in all cell 
lines with high levels of pAKTSer473 in PC3 and LNCaP cells compared with RWPE1 and 
DU145 cells (Figure 8B).  
 
Figure 8. Protein levels of PTEN and phosphorylation of AKT in prostate cell lines. 
Levels of (A) PTEN and (B) pAKTSer473 were determined by Western blot analysis in 
RWPE1, LNCaP, DU145, and PC3 cells. β-actin served as a loading control. 
 
To determine whether the knockdown of PTEN in DU145 cells increased pAKTSer473 
protein levels, we used a specific siRNA to transiently knockdown PTEN expression in 
DU145 cells (Figure 9). Control siRNA was also transfected to serve as a negative 
control. Protein levels of PTEN and pAKTSer473 were determined by Western blot 
analysis, which confirmed that phosphorylation of AKT at Serine 473 levels increased 
while total PTEN protein levels decreased in comparison with cells transfected with 




Figure 9. PTEN knockdown increased protein levels of phosphorylation of AKT in 
DU145 prostate cancer cells. 
Western blot analysis determined relative protein levels of PTEN and pAKTSer473 in 
DU145 prostate cancer cells after transfection with control siRNA or PTEN siRNA. Total 
AKT (tAKT) and β-actin were used as loading controls 
 
4.2 Effects of TGF-β on PTEN Expression in DU145 and RWPE1 Cells  
We investigated the effects of TGF-β isoforms on the expression of PTEN in 
DU145 and RWPE1 cells. DU145 and RWPE1 cells were treated with different 
concentrations of TGF-β1 and/or TGF-β3 for specific times. As shown in Figure 10A, 
TGF-β3 had no effect on the mRNA levels of PTEN in DU145 cells, as determined by 
RT-PCR analysis. We also confirmed the lack of significant TGF-β effects on PTEN 




Figure 10.  TGF-β isoforms have no effect on PTEN mRNA levels in a dose and time-
dependent manner in DU145 cells. 
PTEN gene expression in DU145 cells after treatment with TGF-β3 (5ng/ml) at specific 
time points and different doses of exogenous TGF-β3 for 4 hours for both (A) RT-PCR 
analyses; L-19 was used as a control, and (B) qRT-PCR analysis; GAPDH was used as a 
control. 
 
However, as shown in Figure 11A and B, both isoforms caused a dose-dependent increase 
in PTEN protein levels at specific time points. Treatment with TGF-β3 (5ng/ml) 
significantly increased PTEN protein levels in DU145 cells  at 4 hours (2.7 ± 0.34 fold; P 
< 0.05) and 8 hours (2.0 ± 0.40 fold; P < 0.05); and also in RWPE1 cells  at 4 hours (2.0 
± 0.14 fold; P < 0.05) and 8 hours (1.7 ± 0.31 fold; P < 0.05) (Figure 11A). As shown in 




Figure 11. TGF-β isoforms increase PTEN protein levels in prostate cell lines. 
(A) Western blot analysis of PTEN protein levels in RWPE1 (upper panel) and DU145 
(lower panel) cells after treatment for specific time periods with exogenous TGF-β1 and 
TGF-β3 (5ng/ml). Each bar represents mean ± SEM (n=3). *Significantly different (P < 
0.05) compared with untreated controls.  (B)  DU145 cells were treated with different 
doses of TGF-β1 or TGF-β3 for 4 hours.  β-actin was used as a loading control. Each bar 




dependent manner in DU145 cells after 4 hours at 1ng/ml (1.7 ± 0.26 fold; P < 0.05), 
5ng/ml (2.2 ± 0.12 fold; P < 0.05), and 10ng/ml (2.15 ± 0.103 fold; P < 0.05). As shown 
in Figure 11A and B, TGF-β1 (5ng/ml) treatment also caused an increase in PTEN 
protein levels in both DU145 and RWPE1 cells. In DU145 cells, TGF-β1 treatment 
significantly increased PTEN protein levels at 4 hours (Figure 11A) (1.9 ± 0.10 fold; P < 
0.05), and in a dose-dependent manner after 4 hours at 5ng/ml (1.38 ± 0.149 fold; P < 
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0.05) (Figure 11B), however the increase in PTEN protein levels in TGF-β1 treated  
RWPE1 cells was not statistically significant (Figure 11A). These results suggest that 
both TGF-β1 and TGF-β3 increase PTEN protein levels; however TGF-β3 effects on both 
cell lines are more pronounced. 
4.3 TGF-β Regulates PTEN Protein Stability 
 We have shown in earlier experiments that TGF-β upregulates PTEN protein in 
DU145 cells. To determine this mechanism, we tested the effects of TGF-β on the 
stability of PTEN protein. In our preliminary data, we treated DU145 cells with 
cycloheximide (CHX) (20μg/ml), a protein synthesis inhibitor, for specific time points 
(Figure 12A). We observed that CHX inhibited PTEN protein levels after 24 hours in 
DU145 cells (Figure 12A). Next, we pretreated DU145 cells with CHX (20μg/ml) for 1 
hour followed by TGF-β1 and TGF-β3 (5ng/ml) treatment for 30 hours. As shown in 
figure 12B, both TGF-β1 and TGF-β3 treatment increased PTEN protein levels in the 
presence of CHX in DU145 cells at 30 hours compared to cells treated with CHX only 
for 30 hours. 
 Previous studies have shown that PTEN post-translational modification via 
phosphorylation increases PTEN protein stability.199,200 It has been suggested that 
phosphorylation regulates PTEN activity from a wide variety of upstream signal 
transduction pathways.199,201–203 Previously, TGF-β has been shown to stabilize p21; a 
cell cycle inhibitor; through phosphorylation.204 To determine whether TGF-β regulates 
PTEN stability via phosphorylation, we treated DU145 cells with TGF-β1 and TGF-β3 
(5ng/ml) for specific time points. Relative phosphorylated PTEN (pPTEN) protein levels 
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were determined by Western blot analysis (Figure 12C). Upregulation of pPTEN was 
observed after 4 hours of treatment with TGF-β1 and TGF-β3 (5ng/ml) (Figure 12C). 
These results may suggest that TGF-β mediates the regulation of PTEN protein stability 
via phosphorylation in DU145 prostate cancer cells.  
 
 
Figure 12. PTEN protein stability in response to TGF-β isoforms. 
(A) Western blot analysis of PTEN protein levels in DU145 cells after treatment at specific 
time points with cycloheximide (CHX) (20µg/ml), and β-actin was used as a loading control. 
(B) DU145 cells were pretreated with CHX (20µg/ml) for 1 hour. Cells were then treated 
with TGF-β1 or TGF-β3 (5ng/ml) at specific time points to determine PTEN protein levels. 
β-actin was used as a loading control. Each bar represents mean ± SEM (n=3). Different 
letters represent significant differences among various groups (P< 0.05). (C) Western blot 
analysis of phosphorylated PTEN serine 380 (pPTENSer380) after 4 hour treatment with TGF-
β1 or TGF-β3 (5ng/ml). PTEN was used as a loading control. Each bar represents mean ± 
SEM (n=3).*Significantly different (P < 0.05) compared with untreated controls. 
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4.4 The Effects of TGF-β Isoforms on the Phosphorylation of Smad2 and Smad3 
TGF-β signaling is initiated by binding of the ligand to TGF-βRII that form 
heterodimers with TGF-βRI leading to Smad2 and Smad3 phosphorylation. Therefore, 
we examined whether TGF-β effects on PTEN are mediated by this canonical signaling 
pathway. We determined the effects of TGF-β on the phosphorylation of Smad2 and 
Smad3 in DU145 cells. Western blot analysis showed that TGF-β isoforms induced both 
Smad2 and Smad3 phosphorylation in a time-dependent manner (Figure 13).  
 
 
Figure 13. TGF-β induced Smad signaling in DU145 prostate cancer cells. 
Western blot analyses of phosphorylated Smad2 (pSmad2) and Smad3 (pSmad3) in 
DU145 cells after treatment with TGF-β1 or TGF-β3 (5ng/ml) for 15 and 30 minutes. 
Total Smad (Smad2/3) and β-actin were used as loading controls.  
 
4.5 TGF-β Inhibits Proliferation in DU145 Prostate Cancer Cells 
In previous studies, TGF-β has been shown to exert differential biological effects in 
different prostate cancer-derived cell lines 25,205. To confirm these studies, we first 
41 
 
determined the effects of TGF-β1 and TGF-β3 (5ng/ml) on cell proliferation in DU145 
prostate cancer cells (Figure 14). TGF-β caused a significant inhibition of cell 
proliferation in DU145 cells with no differences in the potencies of the two isoforms. 
Treatment with TGF-β1 resulted in 54% (P < 0.05) inhibition and TGF-β3 resulted in 




Figure 14. Effects of TGF-β isoforms on proliferation in DU145 cells. 
DU145 cells were treated with TGF-β1 or TGF-β3 (5ng/ml) to determine cell 
proliferation. Each bar represents mean ± SEM (n=3). *Significantly different (P < 0.05) 
when compared with appropriate controls. 
 
4.6 The Role of PTEN on TGF-β Effects on Proliferation in Prostate Cancer Cells 
The possible role of PTEN in proliferation of prostate cancer cells and its role in the 
effects of TGF-β on cell proliferation were determined using siRNAs to transiently 
knockdown PTEN proteins in DU145 cells (Figure 15A). Expression of PTEN protein 
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was determined by Western blotting analysis, which confirmed reduced levels (~ 68 %) 
of PTEN protein in comparison with the cells transfected with control siRNA for seventy-
two hours (Figure 15A). DU145 cells were treated with TGF-β1 and TGF-β3 (5ng/ml) for 
48 hours after transfection with PTEN siRNA or Control siRNA (Figure 15A). As 
expected, after transfection with Control siRNA, we observed a significant decrease (P < 
0.001) in proliferation of DU145 cells after treatment with both TGF-β isoforms. On the 
other hand, knockdown of endogenous PTEN resulted in a significant increase in cell 
proliferation which was further increased in TGF-β3 (80%; P < 0.001) treated DU145 
cells (Figure 15A). 
 
Figure 15.  PTEN is involved in inhibitory effects of TGF-β on cell proliferation in 
DU145 and PC3 cells.  
(A)  Cell proliferation in DU145 cells after transfection with control siRNA or PTEN 
siRNA, and (B) PC3 cells after transfection with pcDNA3 GFP empty vector or pcDNA3 
GFP PTEN vector, treated with TGF-β1 or TGF-β3 (5ng/ml) for 3 days. Each bar 
represents mean ± SEM (n=3). Different letters denote significant differences among 
various groups (P < 0.05). Levels of PTEN proteins after transfection with control siRNA 
or PTEN siRNA in DU145 cells, and empty vector or PTEN vector in PC3 cells were 




To further confirm the possible role of PTEN in inhibitory effects of TGF-β, we 
overexpressed PTEN in PC3 cells which are null for PTEN. PC3 cells were transiently 
transfected using the plasmid pcDNA3 GFP PTEN or empty vector pcDNA3 GFP and 
treated with TGF-β1 or TGF-β3 (5ng/ml) to determine the effects on cell proliferation. As 
shown in Figure 15B, expression of PTEN proteins was determined by Western blotting 
which confirmed PTEN overexpression in comparison with the cells transfected with the 
empty vector. TGF-β1 (70%; P < 0.05) and TGF-β3 (45%; P < 0.05) induced a 
significant increase in cell proliferation in PC3 cells transfected with the empty vector 
(Figure 15B). However, proliferation was significantly reduced in PC3 cells 
overexpressing PTEN protein and TGF-β isoforms had no effects on proliferation in these 
cells.  
4.7 TGF-β Effects on Migration in Prostate Cancer Cell Lines. 
TGF-β exerts effects on migration and invasion of specific prostate cancer cells. The 
effects of TGF-β1 and TGF-β3 on migration in selected prostate cell lines (DU145, PC3, 
and LNCaP) under identical experimental conditions were determined by using transwell 
cell migration assay. DU145, PC3, LNCaP cells were treated with either TGF-β isoforms 
and allowed to migrate according to established procedures. As shown in Figure 16A and 
Figure 16B, treatment with both isoforms induced cell migration in PC3 cells (TGF-β1; 
1.2  ± 0.03 migration index; P < 0.05) and TGF-β3; 1.3 ± 0.13 migration index; P < 
0.05), however TGF-β1 did not have any effect on migration in DU145 cells. 
Interestingly, TGF-β3 treatment (1.7 ± 0.20 migration index; P < 0.05) significantly 
induced migration in DU145 cells (Figure 16A). In addition, we determined TGF-β 
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effects on migration in LNCaP cells. It has been reported that LNCaP cells lack the TGF-
βRII, a necessary receptor for TGF-β signaling 9. To confirm this notion, LNCaP cells 
were treated under the same experimental conditions and allowed to migrate according to 
established procedures. As expected, both TGF-β isoforms had no effect on migration in 
LNCaP cells (Figure 16C). On the other hand, epidermal growth factor (EGF), used as a 
positive control, induced cell migration in DU145 (1.7 ± 0.26 migration index; P < 0.05), 
PC3 (1.6 ± 0.07 migration index; P < 0.05), and LNCaP (1.6 ± 0.20 migration index; P < 
0.05) cells (Figure 16A, 16B and 16C).  
 
Figure 16. Effects of TGF-β isoforms on cell migration in prostate cancer cells. 
(A-C)  Cell migration of DU145, PC3, and LNCaP cells across transwell membranes 
were assayed in response to TGF-β1 (5ng/ml), TGF-β3 (5ng/ml), or EGF (10ng/ml) 
treatments. EGF was used as a positive control. Each bar represents mean ± SEM (n=3). 
*Significantly different (P < 0.05) compared with untreated controls. Representative 
images of immunofluorescent cells using DAPI to stain the nucleus of the cells. Cells 
were visualized under 10x objective. 
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4.8 TGF-β Effects on Invasive Properties in DU145 Prostate Cancer Cells. 
Previous studies in our lab have shown that TGF-β isoforms induced invasive 
behavior in PC3 cells, but not in DU145 cells 9,28. To confirm these studies, we 
determined the effects of TGF-β isoforms on cell invasion in DU145 cells using the BD 
BioCoat Matrigel Invasion inserts. As shown in Figure 17, both TGF-β1 and TGF-β3 had 
no effect on invasiveness in DU145 cells, however, EGF induced invasion (2.9 ± 0.66 
invasion index; P < 0.05) in DU145 cells. These results suggest that TGF-β isoforms may 
have differential effects on migration and invasion in prostate cancer cells. 
 
Figure 17. TGF-β isoforms have no effect on invasion in DU145 cells. 
Invasive properties of DU145 cells treated with TGF-β1 (5ng/ml), TGF-β3 (5ng/ml), or 
EGF (10ng/ml) were determined by an invasion assay. Cells were allowed to invade 
through a Matrigel-coated porous membrane for 48 hours. Each bar represents mean ± 







4.9 The Role of PTEN on TGF-β Effects on Migratory Behavior in Prostate Cancer 
Cells 
 
To determine whether PTEN plays a role in TGF-β-mediated effects on migration in 
prostate cancer cells, we performed transient knockdown of PTEN in DU145 cells using 
siRNA specific for PTEN (Figure 18A).  PTEN protein levels were determined by 
Western blot analysis, which confirmed a 54% reduction (P < 0.05) in  DU145 cells 
transfected with PTEN siRNA compared to control siRNA transfected cells (Figure 18A). 
We analyzed migration of DU145 cells after knockdown of PTEN (Figure 18A). DU145 
cells were treated with TGF-β1 and TGF-β3 (5ng/ml) for 48 hours after transfection with 
PTEN siRNA. We observed that both TGF-β isoforms induced migration with a 
significant increase with TGF-β3 (1.6 ± 0.23   fold; P < 0.008) and EGF (1.8 ± 0.07 fold; 
P < 0.008) (Figure 18A).  
Next, we investigated the effects of PTEN expression on TGF-β induced migration in 
PC3 cells. We transiently overexpressed PTEN in PC3 cells (Figure 18B). Expression of 
PTEN proteins were determined by Western blot analysis which confirmed 
overexpression of PTEN in PC3 cells. DU145 served as a positive control for PTEN 
protein expression (Figure 18B). Effects of TGF-β isoforms on cell migration were 
significantly reduced in these cells compared with PC3 cells transfected with empty 
vector (Figure 18B). These results suggest that PTEN overexpression in PC3 cells 




Figure 18.  Lack of PTEN induces cell migration in the presence of TGF-β in prostate 
cancer cells. 
(A)  DU145 cells transfected with control siRNA or PTEN siRNA were treated with 
TGF-β1 or TGF-β3 (5ng/ml), or EGF (10ng/ml) to determine migratory properties in a 
transwell cell migration assay. Levels of PTEN proteins after transfection with control 
siRNA or PTEN siRNA in DU145 cells were determined by Western blotting analysis 
(inset). Each bar represents mean ± SEM (n=3). *Significantly different (P < 0.05) 
compared with untreated controls.  (B)  PC3 cells after transfected with pcDNA3 GFP 
empty vector or pcDNA3 GFP PTEN vector were treated with TGF-β1 or TGF-β3 
(5ng/ml), or EGF (10ng/ml) to determine migration using a transwell migration assay. 
Each bar represents mean ± SEM (n=4). *Significantly different (P < 0.05) when 
compared with untreated controls. Levels of PTEN proteins and β-actin (used as a 
loading control) after transfection with empty vector or PTEN vector, in the presence or 
absence of TGF-β3 or EGF in PC3 cells were determined by Western blotting analysis 
(inset). DU145 was used as a positive control. 
 
4.10 The Role of PTEN in TGF-β Effects on the Phosphorylation of AKT in Prostate 
Cancer Cells 
 
We determined whether or not overexpression of PTEN will affect TGF-β effects on the 
activation of PI3-kinase in PC3 cells treated with TGF-β3 (5ng/ml) (Figure 19). Western 
blot analysis revealed that in response to TGF-β3, PTEN overexpressing PC3 cells had 
significantly lower levels (0.73 ± 0.06 fold: P < 0.05) of AKT phosphorylation compared 
to those transfected with empty vector (Figure 19). These results suggest that 
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overexpression of PTEN in PC3 cells attenuates TGF-β effects on the activation of PI3-
kinase. 
 
Figure 19. PTEN overexpression reduces TGF-β effects on phosphorylation of AKT in 
PC3 cells. 
Western blot analysis showing levels of phosphorylation of AKT (pAKTSer473) with or 
without TGF-β3 (5ng/ml) treatment in PC3 cells after transfection with pcDNA3 GFP 
empty vector or pcDNA3 GFP PTEN vector. Total AKT (tAKT) was used as a loading 
control. Each bar represents mean ± SEM (n=4). *Significantly different (P < 0.05) when 






In this study, we investigated the role of PTEN in TGF-β effects on proliferation and 
migration of prostate epithelial cancer cells. We report that TGF-β has differential effects 
on PTEN protein and RNA levels in prostate cancer cells. TGF-β increases PTEN protein 
levels; however, TGF-β has no effect on mRNA levels in DU145 prostate cancer cells. 
We also show that PTEN may mediate anti-proliferative effects of TGF-β in prostate 
epithelial cells. Our results also revealed that lack of PTEN may enhance TGF-β effects 
on cell migration in prostate cancer cells.  
Prostate cancer occurs and progresses as a result of accumulated genomic mutations 
that lead to unchecked cellular growth and survival of the mutated and dividing cells. 206  
The principle problem arising from prostate cancer and its high rate of mortality is due to 
metastasis of the primary tumor to secondary sites. 207  Cellular migration and invasion 
play fundamental roles in cancer metastasis. Among multiple growth factors, TGF-β has 
been implicated in the regulation of prostate cancer cell proliferation, progression and/or 
metastasis. 208,209  TGF-β is a multiple functional protein that acts as a tumor suppressor 
in normal epithelial cells and in early stages of epithelial cancers by inhibiting 
proliferation and inducing apoptosis. 79  However, in later stages of cancer, cells become 
resistant to growth inhibitory effects of TGF-β, in which TGF-β acts as a tumor promoter 
due to its role in epithelial to mesenchymal transformation (EMT) or promoting the 
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degradation of ECM; all of which aid invasion and metastasis. 9,142–144  In addition, 
previous studies also show that TGF-β effects on migration and invasion of metastatic 
prostate cancer cells are dependent on activation of the PI3-kinase pathway 9,33 by TGF-β, 
as shown by increased phosphorylation of AKT. 32–35,187  However, the intracellular 
mechanisms involved in TGF-β activation of PI3-kinase pathway are largely unknown. 
The PI3-kinase pathway mediates cellular processes such as proliferation, cell survival, 
and migration, and is negatively regulated by PTEN which inhibits those cellular 
functions. Therefore, PTEN may play a role in differential effects of TGF-β on 
proliferation, and migratory behavior by antagonizing PI3-kinase activity in prostate 
cancer cells.  
PTEN mutations and deletions in prostate cancer cells 165,197,210,211 lead to the loss of 
PTEN and constitutive activation of the PI3-kinase/AKT pathway. Several prostate 
cancer-derived cell lines have also been shown to lack expression of PTEN such as a 
homozygous deletion in PC3 cells and frameshift mutation in LNCaP cells. 197  Other cell 
lines derived from normal or cancer cells such as RWPE-1 and DU145 cells maintain 
normal expression of PTEN. These cell lines provide convenient model systems to study 
the role of PTEN and PI3-kinase pathway in prostate cancer cell proliferation, migration, 
and invasion. Our results showed higher constitutive levels of pAKTSer473 in LNCaP and 
PC3 cells as a consequence of PTEN loss, but not in RWPE1 and DU145 cells. On the 
other hand, knockdown of endogenous PTEN by specific siRNA in DU145 and RWPE1 
cells resulted in increased levels of pAKTSer473, indicating enhanced activation of PI3-
kinase pathway.  
51 
 
Earlier studies have addressed the interaction of the PI3-kinase/ PTEN pathway and 
TGF-β signaling pathways in various cell types. Previous reports have shown that TGF-
β1 downregulates PTEN expression in keratinocytes 212 and causes a reduction of PTEN 
mRNA levels in pancreatic cancer cells.213 Moreover, inactivation of TGF-β signaling 
and loss of PTEN cooperate to induce colorectal cancer formation and progression by 
suppressing cell cycle inhibitors.214 Although it is known that loss of PTEN expression 
seems to be frequent in many human tumors, the expression of PTEN has been associated 
with inhibitory effects on proliferation, migration, and induction of apoptosis in vitro and 
in vivo.213,215,216  In the current study, we studied the effects of TGF-β1 and TGF–β3 on 
PTEN expression in DU145 and RWPE1 cells. Our results show that while TGF-β 
isoforms had no effect on PTEN mRNA levels; they induced an increase in PTEN protein 
in both DU145 and RWPE1 cells. TGF-β induced increase in PTEN protein levels may 
suggest that the level of PTEN may be regulated by TGF-β via other mechanisms such as 
protein stability and protein degradation. It has been reported previously that PTEN 
activity may be highly regulated on many levels by post-transcriptional and 
posttranslational mechanisms 186. Previous groups have demonstrated that the C-terminal 
end of PTEN and PTEN posttranslational modification via phosphorylation upregulates 
PTEN protein stability. 199,200  Post-transcriptionally, PTEN can be modified as a result of 
phosphorylation by casein kinase 2 (CK2) and has been previously demonstrated that 
PTEN protein phosphorylation by CK2 was important for proteasome-mediated PTEN 
protein degradation. 199  Other studies have shown that compared to phosphorylated 
PTEN, dephosphorylated PTEN has decreased stability 199–201,217  While  it has been 
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suggested that phosphorylation regulates PTEN activity from a wide variety of upstream 
signal transduction pathways, 199,201–203 previous studies confirmed that TGF-β can 
regulate protein stability via posttranslational modifications. 204,218–220  One study 
revealed that TGF-β increases nuclear p27 levels by preventing proteasomal degradation, 
specifically by downregulating ubiquitin E3 ligase subunits in endometrial carcinoma 
cells.220  Our results show that both TGF-β1 and TGF-β3 upregulated PTEN 
phosphorylation in DU145 cells. These results indicate that TGF-β may mediate the 
phosphorylation of PTEN regulating its stability by inhibiting the proteasomal 
degradation pathway in prostate cancer cells.  
Our results suggest that increased PTEN protein levels in DU145 cells and RWPE1 
cells, in response to TGF-β, may lead to a reduction in cell proliferation in these cells. 
Our laboratory has previously shown that TGF-β inhibits cell proliferation in RWPE1 
and DU145 cells, whereas PC3 (PTEN null) prostate cancer cells are resistant to these 
growth inhibitory effects. 26 Our results show that PTEN knockdown by specific siRNA 
resulted in a significant increase in cell proliferation in the presence of TGF-β1 and TGF-
β3 isoforms. These results indicate that reduced PTEN protein levels in DU145 cells 
enhanced TGF-β effects and that PTEN may be required for inhibitory effects of TGF-β 
on cell proliferation in these cells. The possible role of PTEN in cell proliferation was 
also confirmed by our experiments where we transiently overexpressed PTEN in PC3 
cells, which led to inhibition of cell proliferation. Our results are very similar to recently 
reported findings indicating that the overexpression of PTEN in PC3 cells inhibited cell 
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proliferation, and decreased IGF-I-induced phosphorylation of IRS-1, the downstream 
substrate of IGF-IR. 221  
Previous studies have shown that TGF-β1 and TGF-β3 exert differential effects on 
migration and invasion in prostate cancer cells.9,25  It has been indicated that TGF-β3 
exerts more potent effects on migratory and invasive behavior. Although both TGF-β 
isoforms induced migratory and invasive behavior in PC3 cells, 9,25  both isoforms had no 
effects on migratory behavior in DU145 cells 9. In another study, TGF-β1 induced cell 
migration and invasion in PC3 cells but not in DU145 cells using the transwell insert cell 
migration assay, 25,28  TGF-β3 was not investigated in these studies. Interestingly, our 
results show that while TGF-β1 had no effects on migration in DU145 cells, TGF-β3 
significantly induced migration in both DU145 and PC3 cells. Interestingly, TGF-β3 had 
no effects on invasive behavior in DU145 cells. These results may suggest that TGF-β3 is 
significantly more potent than TGF-β1 and exert differential effects in prostate cancer 
cells. These observed effects in both DU145 and PC3 cells are specific to TGF-β, since 
LNCaP cells (used as negative controls due to lack of TGF-βRII) were unresponsive to 
both isoforms of TGF-β. 9,222  Similar differential role of TGF-β isoforms is also 
supported in breast carcinomas, where high expression of TGF-β3 correlates with 
decreased overall survival rate. 146,147 It has been confirmed that the isoform-specific 
roles of TGF-β on cell migration and invasion are mediated by TGF-βRI and Smad3 
dependent activation of PI3-kinase pathway in metastatic prostate cancer cells. 9 Previous 
studies have implicated a role for PTEN in repressing the pro-tumorigenic effects of 
TGF-β; reconstitution of PTEN expression in PTEN-null cells blocked TGF-β-induced 
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invasion, but did not modulate TGF-β-mediated growth regulation. 50  Similarly, in 
keeping with these studies, our results show that in the presence of TGF-β, knockdown of 
PTEN enhanced migration in DU145 cells, whereas PTEN overexpression reduced 
migratory behavior in PC3 cells in response to TGF-β. These results indicate that reduced 
PTEN protein levels in DU145 cells enhance TGF-β effects on migration, and that PTEN 
may play a role in TGF-β mediated effects in regulating tumor cell metastasis. In PC3 
cells, overexpression of PTEN has been shown to be associated with a decrease in the 
levels of pAKTSer473.  221  Previously, it has been shown that TGF-β can activate PI3-
kinase pathway in prostate cancer cells as shown by increased phosphorylation of AKT, 
32–35,187 and activation of this pathway is required for its effects on increased migration 
and invasion of these cells. 29 Here, we show that overexpression of PTEN in PC3 cells 
reduced the phosphorylation of AKT and invasive behavior in response to TGF-β3. These 
results suggest that PTEN inhibits PI3-kinase-dependent AKT phosphorylation, and that 






Our results demonstrate that TGF-β increases protein levels of PTEN in prostate 
cancer cells; however, TGF-β has no effect on mRNA levels of PTEN in these cells. In 
addition, TGF-β upregulated the phosphorylation of PTEN in prostate cancer cells. This 
suggests that TGF-β mediates the regulation of PTEN protein stability via 
phosphorylation in these cells. We also show that lack of PTEN led to increased TGF-β 
effects on migration in prostate cancer cells, whereas overexpression of PTEN, in PTEN 
null prostate cancer cells, inhibited TGF-β effects on cell migration. In addition, 
overexpression of PTEN in these cells decreased TGF-β-induced phosphorylation of 
AKT, as a result of inhibition of the PI3-kinase/AKT signaling pathway. Furthermore, 
increased proliferation and enhanced TGF-β effects on cell migration and invasion after 
knockdown of endogenous PTEN could explain the upregulation of TGF-β signaling and 
increased tumor growth and metastatic behavior in prostate cancer cells that have 
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